-+ 0.00%
-+ 0.00%
-+ 0.00%

Samsung C&T Says Samsung Biologics' PolyPeptide Tender Offer Draws 97.98% Acceptance

PUBT·11/06/2026 09:05:15
Listen to the news
Samsung C&T Says Samsung Biologics' PolyPeptide Tender Offer Draws 97.98% Acceptance
  • Samsung C&T's Nov. 6, 2026, correction disclosed final tender acceptances of 97.98% for Samsung Biologics' PolyPeptide takeover.
  • Acceptances totaled 32,350,302 shares; Samsung Biologics plans to secure 100% ownership through measures including a compulsory purchase under Swiss law.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung C&T Corporation published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261106800926), on November 06, 2026, and is solely responsible for the information contained therein.